Search

Your search keyword '"Soma, Lorinda A."' showing total 34 results

Search Constraints

Start Over You searched for: Author "Soma, Lorinda A." Remove constraint Author: "Soma, Lorinda A." Search Limiters Full Text Remove constraint Search Limiters: Full Text
34 results on '"Soma, Lorinda A."'

Search Results

4. Acquired CD38 Gene Deletion as a Mechanism of Tumor Antigen Escape in Multiple Myeloma

8. Dose-Adjusted EPOCH Versus Hypercvad As Initial Treatment for Adults with Acute Lymphoblastic Leukemia (ALL): A Retrospective Matched Cohort Comparison

9. CD19 CAR-T cells of defined [CD4.sup.+]:[CD8.sup.+] composition in adult B cell ALL patients

10. Lamin B1 deletion in myeloid neoplasms causes nuclear anomaly and altered hematopoietic stem cell function

11. CD19 CAR–T cells of defined CD4+: CD8+ composition in adult B cell ALL patients

12. Loss of Lamin B1 in Myeloid Neoplasms with 5q Deletion Causes Myeloid-Biased Hematopoiesis and Pelger-Huet Nuclear Anomaly

13. Reduced-Intensity Therapy with Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Yields Durable Remissions in Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL): Final Results of a Phase II Trial

14. Supplemental Material, sj-pdf-3-apc-10.1177_2374289521990823 - Entrustable Professional Activities in Hematopathology Pathology Fellowship Training: Consensus Design and Proposal

15. Supplemental Material, sj-pdf-2-apc-10.1177_2374289521990823 - Entrustable Professional Activities in Hematopathology Pathology Fellowship Training: Consensus Design and Proposal

16. Supplemental Material, sj-pdf-4-apc-10.1177_2374289521990823 - Entrustable Professional Activities in Hematopathology Pathology Fellowship Training: Consensus Design and Proposal

17. Supplemental Material, sj-pdf-1-apc-10.1177_2374289521990823 - Entrustable Professional Activities in Hematopathology Pathology Fellowship Training: Consensus Design and Proposal

18. Does Detection of

20. Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

21. Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL): Initial Results of a Phase II Trial

22. Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study

23. Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin

24. Poor Outcomes Among Patients Failing Dose-Adjusted EPOCH in Aggressive Lymphoma: A Collaborative, Retrospective Study

25. Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes

26. Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia

27. Does Detection of <20% Lymphoblasts in Patients with CML Herald Imminent Blast Crisis? a Study from BCR::ABL1Pathology Group

28. Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma

29. Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin

33. A Rapidly Enlarging Thyroid.

34. Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.

Catalog

Books, media, physical & digital resources